News

Protein Sciences Corporation News

Web Site: http://www.proteinsciences.com
- Sanofi Pasteur Inc. 1000 Research Pkwy., Meriden, CT 06450 - 7159
Tel: (203) 686-0800 Fax: (203) 686-0268

Protein Sciences Corporation, founded in 1983, is a privately held vaccine company with headquarters in Meriden, Connecticut. PSC's mission is to save lives and improve health.

View all News Articles for Protein Sciences Corporation

Protein Sciences Adds Vaccine Commercialization and Development Experts to its Core Team and Board

August 25, 2013

The Company has hired vaccine marketing and sales veteran Brad Thompson to be its Chief Commercial Officer, elected renowned vaccine expert Albertus D.M.E. Osterhaus, known as "Ab", to its Board of Directors, and appointed Cheryl L. Cohen, a pharmaceutical commercialization specialist and Chief Commercial Officer of Medivation, Inc., Senior Strategic Advisor to the Board.

Dr. Manon Cox, President and CEO of Protein Sciences said, "Flublok is a game changer. Now that we have it approved, bringing in marketing experts like Brad and Cheryl to launch the product is vitally important." She added, "Equally essential is having the support of international thought leaders like Ab to keep us at the forefront of vaccine innovation as we develop new products. We are thrilled to have them."

Mr. Thompson joins Protein Sciences following a 25 year career in the pharmaceutical industry with Pfizer, Wyeth, American Cyanamid and Schering Plough, where he held positions in Sales, Sales Management, U.S. Marketing, Global Marketing and New Products Marketing. He has spent over 16 years specializing in the Vaccines market and played key roles in the U.S. and global launches of a pneumococcal conjugate vaccine. He has also worked on the commercialization of rotavirus, influenza, DTaP and Hib vaccines.

Ms. Cohen has spearheaded the successful commercial launches of multiple new products over the course of her career, including leading the $1+ billion per year Remicade® U.S. rheumatoid arthritis business and its 170-person sales and marketing team for Centocor, Inc., a Johnson & Johnson company. She has also served as the Vice President, Strategic Commercial Group, of Health Care Systems, Inc., a Johnson & Johnson company accountable for managed markets, contracting and supply chain, and was President of CLC Consulting, a pharmaceutical and biotechnology consulting firm specializing in new product start-up and commercialization.

Dr. Osterhaus has a long standing track record as a scientific researcher and is an international authority in the field of "Viroscience." Over the years he has been responsible for the identification of more than 20 novel human and animal viruses, vaccine development and anti-viral drug development against several viruses including influenza viruses. He has served as member and chairman of many international scientific committees, most notably three WHO reference centers, the Dutch Influenza Centre, the Dutch Health Council and the European Scientific Working group on Influenza (ESWI). Multiple awards, prizes, guest lecture invitations, organizer of international meetings and editorships of scientific journals highlight his international recognition.

Protein Sciences Corporation is a vaccine development and protein production company that is dedicated to saving lives and improving health through the creation of innovative vaccines and biopharmaceuticals. On January 16, 2013, the U.S. FDA approved Flublok, the world's first recombinant protein-based vaccine for the prevention of seasonal influenza disease, for use in adults 18-49 years old. Flublok and its sister vaccine, Panblok®, that is designed to protect against pandemic influenza, have been developed in partnership with BARDA through Contract No. HHS0100200900106C. Learn more at Protein Sciences website or at the Flublok website.

Member News is provided as a service of the Midstate Chamber of Commerce and is also featured in the monthly "Chamber News" newsletter mailed to members.